Local Administration of 1% Ubretid in the Handling of Glaucoma, Myasthenia Gravis and Esotropia

S, Ishikawa; Tsukahara, Shigeo; Satō, Yoshio

doi:10.1159/000305931

Cited by 10 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It and other carbamate ChE inhibitors have been used to treat myasthenia gravis in Asia, the Middle East, and Europe. [2][3][4][5] Distigmine has also been used to treat glaucoma in Japan. [6][7][8] Distigmine has also been applied as a remedy for dysuria in Japan since its release there in 1968.…”

Section: Introductionmentioning

confidence: 99%

“…[2][3][4][5] Distigmine has also been used to treat glaucoma in Japan. [6][7][8] Distigmine has also been applied as a remedy for dysuria in Japan since its release there in 1968. It was reported that distigmine has a therapeutic effect on neurogenically underactive bladder caused by surgery, spinal cord injury, and chronic diseases such as diabetes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Distigmine on the Mechanical Activity of Urinary Bladder Smooth Muscle

Obara

Tanaka

2019

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Distigmine bromide (distigmine) is a reversible carbamate cholinesterase (ChE) inhibitor. Its principle clinical application is in the treatment of myasthenia gravis. Distigmine is also used as a remedy for dysuria and glaucoma. Its effectiveness in the management of dysuria has been demonstrated in several clinical reports. Distigmine may improve (enhance) urinary bladder smooth muscle (UBSM) contraction during micturition by inhibiting acetylcholine (ACh) decomposition. However, the pharmacological effects of distigmine on UBSM have not been adequately studied so far. In this review article, we summarize the reported effects of distigmine on the contractile responses elicited by exogenous and endogenous ACh in isolated UBSM preparations. We also discuss the effects of distigmine on the UBSM basal tone and the contractile response of UBSM to ATP, which is co-released with ACh from parasympathetic nerve terminals.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effects of Distigmine on the Mechanical Activity of Urinary Bladder Smooth Muscle

Obara

Tanaka

2019

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…1). Distigmine is used clinically in some Asian and European countries, including Japan and Germany, [2][3][4][5][6][7][8] and the main clinical indication for distigmine is myasthenia gravis. 2,9) However, in Japan, distigmine has also been used for glaucoma 3) and an underactive bladder.…”

mentioning

confidence: 99%

“…Distigmine is used clinically in some Asian and European countries, including Japan and Germany, [2][3][4][5][6][7][8] and the main clinical indication for distigmine is myasthenia gravis. 2,9) However, in Japan, distigmine has also been used for glaucoma 3) and an underactive bladder. [4][5][6][7][8] The effectiveness and usefulness of distigmine for underactive bladder treatment have been shown in many clinical studies.…”

mentioning

confidence: 99%

Long-Lasting Inhibitory Effects of Distigmine on Recombinant Human Acetylcholinesterase Activity

Obara

Chino

Tanaka

2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

To elucidate the mechanism whereby distigmine, an underactive bladder remedy, potentiates urinary bladder contractions long-lastingly, the inhibition of recombinant human acetylcholinesterase (rhAChE) by distigmine was investigated. A centrifugal ultrafiltration device, Nanosep ® 10K, was used to separate rhAChE and a bound inhibitor from an unbound inhibitor, reaction substrate, and reaction product. This allowed the same aliquot of rhAChE to be repeatedly assayed for up to 48 h to confirm the long-lasting binding of an inhibitor. Cholinesterase (ChE) inhibitors, distigmine, pyridostigmine, neostigmine, and ambenonium, were tested. The dissociation rate constant (k diss ) and dissociation half-life (t 1/2 ) of each inhibitor were determined based on the changes in rhAChE activity. Within 2-4 h after removing pyridostigmine, neostigmine, or ambenonium, the rhAChE activity was restored to the control levels. The k diss values for pyridostigmine, neostigmine, and ambenonium were calculated to be 0.51 0.05, 0.66 0.03, and 1.41 0.08 h 1 , and the t 1/2 values were calculated to be 1.36, 1.05, and 0.49 h, respectively. With distigmine, the rhAChE activity initially dropped to 17% of that in the control and then slowly recovered to only 50% by 48 h after drug removal. The k diss and t 1/2 values of distigmine were calculated to be 0.012 0.001 h 1 and 57.8 h, respectively. Based on the t 1/2 values, distigmine was judged to dissociate from acetylcholinesterase (AChE) 40-120-fold slower than the other ChE inhibitors did. This may explain the long-lasting potentiation of urinary bladder contractions and motility by distigmine as a treatment for an underactive bladder. Key words distigmine bromide; acetylcholinesterase; cholinesterase inhibitorDistigmine is a reversible cholinesterase (ChE) inhibitor from the class of carbamates. It was chemically synthesized by Schmid 1) and has a chemical structure consisting of two molecules of pyridostigmine connected by hexamethylene bonds (Fig. 1). Distigmine is used clinically in some Asian and European countries, including Japan and Germany, 2-8) and the main clinical indication for distigmine is myasthenia gravis.2,9) However, in Japan, distigmine has also been used for glaucoma 3) and an underactive bladder. 4-8)The effectiveness and usefulness of distigmine for underactive bladder treatment have been shown in many clinical studies. [4][5][6][7][8] However, the experimental evidence to support these clinical reports was not convincing. Therefore, our laboratory started pharmacological studies on the effects of distigmine on urinary bladder (UB) motility and has previously reported results supporting the clinical effectiveness and usefulness of distigmine. [10][11][12][13][14][15][16][17][18] The most remarkable pharmacological characteristic of distigmine was the persistence of its effect. In particular, distigmine was found to potentiate the UB internal pressure via the micturition reflex for more than 12 h. 17)Interestingly, the long-lasting potentiating effect of distigmine o...

show abstract

1 proz. Ubretid in der Glaukomtherapie

Benedikt¹

1972

Cornea

View full text Add to dashboard Cite

Local Administration of 1% Ubretid in the Handling of Glaucoma, Myasthenia Gravis and Esotropia

Cited by 10 publications

References 11 publications

Effects of Distigmine on the Mechanical Activity of Urinary Bladder Smooth Muscle

Effects of Distigmine on the Mechanical Activity of Urinary Bladder Smooth Muscle

Long-Lasting Inhibitory Effects of Distigmine on Recombinant Human Acetylcholinesterase Activity

1 proz. Ubretid in der Glaukomtherapie

Contact Info

Product

Resources

About